new version V2017

Dapagliflozin antidiabetic drugs
Description Results

BMS-512148 - BMS512148 - BMS 512148 - forxiga - dapagliflozin      

  • Group by...

pdf
TrialStudied treatmentControl treatmentpatientsROBResultNCT

diabetes type 2

Kohandapagliflozinplacebo - NCT00972244
Weberdapagliflozinplacebo (on top standard treatment) - NCT01195662
MB102073dapagliflozinplacebo (on top standard treatment) - NCT01137474
MB102035dapagliflozinplacebo (on top standard treatment) - NCT00976495
MB102061dapagliflozinplacebo add on DPP-4 - NCT00984867
Kohandapagliflozin + merformindapagliflozin - NCT00643851
KOhandapagliflozinplacebo Low risk of bias - NCT00736879
Kohandapagliflozinplacebo - NCT00663260
Komoroski (MB102007), 2009dapagliflozinplacebo Exploratory - NCT00162305
List (MB102008), 2009dapagliflozinplacebo Exploratory - NCT00263276
Wilding (MB102009), 2009dapagliflozinplacebo (add on insulin) - NCT00357370
Ferrannini (MB102013), 2010dapagliflozinplacebo - NCT00528372
Bailey (MB102014), 2010dapagliflozinplacebo (add on MET) Exploratory - NCT00528879
Nauck, 2011dapagliflozindlipizide add on metformin - NCT00660907
Strojek, 2011dapagliflozin + Glimepirideglimepiride - NCT00680745
Wilding, 2012dapagliflozinplacebo (add on insulin) - NCT00673231
Bolinder, 2012dapagliflozinplacebo (add on MET) - NCT00855166
Rosenstock, 2012dapagliflozinplacebo (add on TZD) - NCT00683878
Kaku, 2014dapagliflozinplacebo - NCT01294423
Yang, 2015dapagliflozin - NCT01095666
Mathieu, 2015dapagliflozinplacebo (add on MET + SAXA) - NCT01646320
Schumm-Draeger , 2015dapagliflozinplacebo (add on MET) - NCT01217892
Matthaei, 2015dapagliflozinplacebo (add on MET+SU) - NCT01392677
Cefalu, 2015dapagliflozinplacebo (on top standard treatment) - NCT01031680
Rosenstock, 2015dapagliflozinSaxagliptin (add on MET) - NCT01606007
MB102034, 2016dapagliflozin + merforminmetformin or dapa - NCT00859898
Leiter, 2016dapagliflozinplacebo (on top standard treatment) - NCT01042977
DECLARE TIMI 58, 2018dapagliflozinplacebo Exploratory - NCT01730534
D1695C00001 ongoing dapagliflozindapagliflozin - NCT02582814
DERIVE ongoing dapagliflozinplacebo - NCT02413398
MB102-210 ongoing dapagliflozinplacebo - NCT02383238
DECLARE-TIMI 58 ongoing dapagliflozinplacebo - NCT01730534
D1693C00002 ongoing dapagliflozinplacebo - NCT01257412
D1690C00023 ongoing dapagliflozinplacebo - NCT02547935
D5553C00003 ongoing dapagliflozinplacebo (add on EXE) - NCT02229396
MB102-137 ongoing dapagliflozinplacebo (add on INS) - NCT02096705
D1683C00005 ongoing dapagliflozinplacebo (add on SAXA + MET) - NCT02681094
MB102-054 ongoing dapagliflozinplacebo (add-on MET) - NCT01095653
CV181-363 ongoing dapagliflozinsaxa (add on MET) - NCT02284893
CV181-365 ongoing dapagliflozinSaxagliptin (add on MET) - NCT02419612
0431-838 ongoing dapagliflozinSitagliptin (add on mET) - NCT02532855



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons